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ABSTRACT
Background and Objectives: We present a multicenter study of a new endoscopic ultrasound‑guided fine‑needle
biopsy (EUS‑FNB) needle (Acquire, Boston Scientific, Natick, MA). The aim of the study was to analyze the needle’s
clinical performance when sampling solid lesions and to assess the safety of this device. Methods: We performed a
multicenter retrospective study of patients undergoing EUS‑FNB during July 1–November 15, 2016. Results: Two hundred
patients (121 males and 79 females) underwent EUS‑FNB of solid lesions with the Acquire needle. Lesions included
solid pancreatic masses (n = 109), adenopathy (n = 45), submucosal lesions (n = 34), cholangiocarcinoma (n = 8), liver
lesions (n = 6), and other (n = 8). Mean lesion size was 30.6 mm (range: 3–100 mm). The mean number of passes per target
lesion was 3 (range: 1–7). Rapid onsite cytologic evaluation (ROSE) by a cytologist was performed in all cases. Tissue
obtained by EUS‑FNB was adequate for evaluation and diagnosis by ROSE in 197/200 cases (98.5%). Data regarding the
presence or absence of a core of tissue obtained after EUS‑FNB were available in 145/200 procedures. In 131/145 (90%)
of cases, a core of tissue was obtained. Thirteen out of 200 patients (6.5%) underwent some form of repeat EUS‑based
tissue acquisition after EUS‑FNB with the Acquire needle. There were no adverse events. Conclusion: Overall, this study
showed a high rate of tissue adequacy and production of a tissue core with this device with no adverse events seen in
200 patients. Comparative studies of different FNB needles are warranted in the future to help identify which needle type
and size is ideal in different clinical settings.
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INTRODUCTION
EUS‑FNA is a well‑established technique to evaluate
solid and cystic lesions within or adjacent to the
gastrointestinal tract. It is widely regarded as safe,
accurate, and has a low complication rate.[1,2] Despite
extensive research and clinical experience, it has been
difficult to identify meaningful differences between
different FNA needle types and sizes from different
manufacturers.[3]
Recent years have seen the development and
commercial release of several fine‑needle biopsy (FNB)
needles, which are designed primarily to obtain core
tissue samples. These FNB needles allow acquisition
of larger tissue samples which in turn are helpful
for both histologic and cytologic evaluation. To date,
there have only been limited studies on EUS‑guided
FNB (EUS‑FNB) needles with regard to their uses,
safety, and tissue acquisition capabilities.
We present a multicenter study of a new EUS‑FNB
needle (Acquire, Boston Scientific, Natick, MA). The
aim of the study was to analyze the needle’s clinical
performance when sampling solid lesions and to assess
the safety of this device.
METHODS
We performed a multicenter and retrospective study
of patients undergoing EUS‑FNB with the Acquire
needle between July 1 and November 15, 2016. Patients
were included if they were >18 years of age and had
a solid lesion identified that warranted biopsy. Patients
were excluded if they were <18 years of age, pregnant,
prisoners, or were undergoing EUS‑guided biopsy of a
cystic lesion. Liver biopsies to evaluate for parenchymal
disease were excluded from the study.
Needle tip echogenicity was graded on a scale of 1–4,
with 1 being the most echogenic and 4 being the least
echogenic. Nearly 95% of users rated the needle tip
echogenicity as a 1 and 5% rated it as a 2. Ease of
puncture was graded on a scale of 1–4, with 1 being
the easiest and 4 being the most difficult. These factors
were assessed in regards to the needle under study and
not in comparison to other needles.
Tissue was felt to be adequate if a cytologist could
render a final diagnosis based on the supplied tissue.
The presence of a core was assessed grossly and
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microscopically by the presence of a solid tissue
core (not a clot) that produced histology when
evaluated after formal processing by pathology.
An excel spreadsheet that enumerated data
parameters for all patients was completed at each
site. This spreadsheet included but was not limited to
demographic information about the patients; the type,
size, and location of the target lesion; the needle size,
number of passes; and information about the tissue
analysis including how passes were used (cytologic
analysis, histologic analysis, or both), the presence or
absence of ROSE, the adequacy of the specimen, and
the final diagnosis; as well as the presence or absence
of any adverse events.
The study was Institutional Review Board approved at
all sites.
RESULTS
Over the study period, 200 patients (121 males and
79 females) with a mean age of 63 years underwent
EUS‑FNB of solid lesions with the Acquire needle
[Table 1]. Some patients underwent biopsies of multiple
sites during their procedures. Eight patients (4%)
required EUS‑FNB after a prior nondiagnostic
EUS‑FNA procedure. Seven patients (3.5%) underwent
repeat EUS‑FNB after a prior nondiagnostic EUS‑FNB
procedure. No data are available regarding the type or
size of needle used in these nondiagnostic EUS‑FNA
and FNB procedures. One hundred and eighty‑six
patients underwent FNB with a 22‑gauge needle and
14 patients underwent FNB with a 25‑gauge needle. No
patients underwent FNB with a 19‑gauge needle as it
was not available commercially at the time of the study.
Target lesions undergoing FNB included
solid
pancreatic
masses
(n
=
109),
adenopathy (n = 45), submucosal lesions (n = 34),
cholangiocarcinoma (n = 8), liver lesions (n = 6), and
other sites (n = 8) [Table 2]. Sixty‑two pancreatic
masses were located in the head of the gland, 3 were
located in the uncinate process, 4 were located in
the genu, 27 were located in the body, and 13 were
located in the tail. Eleven pathologically enlarged nodes
were located in the mediastinum, 7 were celiac nodes,
2 were gastrohepatic ligament nodes, 11 were porta
hepatis nodes, 9 were peripancreatic nodes, and 3 were
perirectal nodes. In two patients, the location of the
adenopathy was not specified. One submucosal lesion
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was in the esophagus, 24 were in the stomach, 2 were
in the duodenum, and 7 were in the rectum.
The overall mean target lesion size was 30.6 mm (range:
3–100 mm). The mean number of passes per target
lesion was 3 (range: 1–7).
The technique of tissue acquisition during the FNB
procedure was left to the discretion of the individual
endoscopists. The “slow pull” technique whereby the
stylet was slowly withdrawn a distance of 6–12 inches
during needle actuations was used in 74% of biopsies,
a dry needle with a vacuum syringe was used in 22%
of biopsies, and, in 4% of biopsies, the stylet was
completely removed, and the needle was flushed with
saline before starting actuations. In addition to the
technique for needle biopsy utilized, the “fanning”
approach to needle actuations was performed in
65/200 (32.5%) patients.

Figure 1. Cell block from an Acquire needle biopsy showing intact
cores with infiltrating malignant glands and single cells, consistent
with adenocarcinoma (H and E, ×10)

Ninety‑four percent of users rated the ease of puncture
as a 1 with 6% of users rating it a 2. Ease of needle
actuation was graded on a scale of 1–4, with 1 being
the easiest and 4 being the most difficult. Ninety‑three
percent of users rated the ease of needle actuation a
1 and 7% of users rated ease of needle actuation a 2.
ROSE by a cytologist was performed in all cases.
Tissue obtained by EUS‑FNB was felt to be
adequate for evaluation and diagnosis by ROSE in
197/200 cases (98.5%). Data regarding the presence or
absence of a core of tissue obtained after EUS‑FNB
were available in 145/200 procedures. In 131/145 (90%)
of cases, a core of tissue was obtained [Figures 1-3].
In 14/145 (10%) of cases, a visible core of tissue
was not obtained. Thirteen out of 200 patients (6.5%)
underwent some form of repeat EUS‑based tissue
acquisition after undergoing EUS‑FNB with the Acquire
needle.

Figure 2. Cell block from an Acquire needle biopsy showing an intact
core harboring malignant cells with scant cytoplasm and heavy crush
artifact within a fibrous background. The morphology is suggestive of
small cell (poorly differentiated) neuroendocrine carcinoma (H and E)

Twelve patients (6%) had FNB samples sent for
histologic analysis only. One hundred and three out
of 200 (51.5%) patients had their samples divided
between cytologic and histologic analysis, and
85/200 patients (42%) had their samples sent for
evaluation by cytology only.
A final histologic diagnosis was available for
198/200 patients (99%). A final diagnosis of pancreatic
adenocarcinoma was made in 86 patients (43%),
pancreatic neuroendocrine tumor in 21 patients (10.5%),

Figure 3. Photomicrograph of the same patient as Figure 2 cells
showing diffuse cytoplasmic staining for synaptophysin, supporting
the diagnosis of small cell carcinoma (×10)

ENDOSCOPIC ULTRASOUND / VOLUME 8 | ISSUE 2 / MARCH-APRIL 2019

101

[Downloaded free from http://www.eusjournal.com on Wednesday, May 8, 2019, IP: 147.140.127.133]

Adler, et al.: Multicenter evaluation of a new EUS core biopsy needle

Table 1. Demographics (total sample size=200)
n
Age
Mean±SD
Median
Range
Male, n (%)
Female
Male

63.025±14.54
63
82
79 (39.50)
121 (60.50)

SD: Standard deviation

Table 2. Results (total sample size=200)
Summary
Target lesions, n (%)
Solid pancreatic masses
Head
Uncinate process
Genu
Body
Tail
Adenopathy
Mediastinum
Celiac
Gastrohepatic ligament
Porta hepatis
Peripancreatic
Perirectal
Not specified
Submucosal lesions
Esophagus
Stomach
Duodenum
Rectum
Cholangiocarcinoma
Liver lesions
Other sites
Target lesion (mean, range)
Size
Number of passes
Technique of tissue acquisition, n (%)
Slow pull
Dry needle with vacuum syringe
Stylet removed and needle
flushed with saline
Final diagnosis, n (%)
Pancreatic adenocarcinoma
Pancreatic neuroendocrine tumor
GIST
Lymphoma
Lesions metastases of
established malignancies
No evidence of malignancy
Other (leiomyomas, lipomas, ectopic
pancreas, and granulomatous disease)

109 (0.55)
62 (0.57)
3 (0.03)
4 (0.03)
27 (0.25)
13 (0.12)
45 (0.23)
11 (0.24)
7 (0.16)
2 (0.04)
11 (0.24)
9 (0.20)
3 (0.07)
2 (0.04)
34 (0.17)
1 (0.03)
24 (0.71)
2 (0.06)
7 (0.21)
8 (0.04)
6 (0.03)
8 (0.04)
30.6 mm (3‑100 mm)
3 (1‑7)
0.74
0.22
0.04
0.99
86 (0.43)
21 (0.105)
13 (0.065)
5 (0.025)
11 (0.055)
39 (0.195)
23 (0.115)

GIST: Gastrointestinal stromal tumors

gastrointestinal stromal tumor in 13 patients (6.5%), and
lymphoma in five patients (2.5%). In 11 patients (5.5%),
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lesions were found to be metastases of established
malignancies. Thirty‑nine patients (19.5%) had no
evidence of malignancy seen in their specimens and
23 patients (11.5%) had a variety of other diagnoses
including leiomyomas, lipomas, ectopic pancreas, and
granulomatous disease/sarcoidosis.
There were no adverse events reported in any patient
undergoing EUS‑FNB.
DISCUSSION
The introduction of FNB needles to clinical practice
has produced a shift within the practice of EUS.
Formerly, all lesions (with rare exceptions) were
sampled by FNA and FNB was rarely performed
in practice. An older core needle (TruCut, Cook
Endoscopy, Winston Salem NC) has been commercially
available for years and is an effective tool but never
saw widespread adoption. This was likely related to
somewhat cumbersome nature of the device and limited
maneuverability of this needle when the echoendoscope
is in a flexed position.[4‑7]
A 2013 pilot study from our group on an early
EUS‑FNB needle (ProCore, Cook Endoscopy, Winston
Salem, NC) that evaluated 36 patients (18 of whom
underwent EUS‑FNA and 18 of whom underwent
EUS‑FNB in matched lesion types) showed that
the mean number of passes to achieve adequacy
varied between the groups (2.94 for the standard
22‑gauge needle group vs. 2.11 for the core needle
group [P = 0.03]) with no meaningful difference in
case duration between needle groups. Overall, the two
needle groups in this study demonstrated similar results
for the cytology parameters, amount of diagnostic cell
block material, adequacy, and accuracy. Another study
of this needle reached similar results when comparing
it to standard FNA needles.[8] Additional data regarding
this needle have been more encouraging.[9‑11]
A different pilot study from our group published
in 2016 using a different FNB needle (Shark Core,
Covidien, Dublin, Ireland) evaluated thirty patients,
15 of whom underwent EUS‑FNA and 15 of
whom underwent EUS‑FNB in matched lesion types.
The core needle required fewer needle passes to
obtain diagnostic adequacy than the standard needle
((χ2(1) = 11.3, P < 0.001). The core needle required
1.5 passes to reach adequacy, whereas the standard
needle required three passes. For cases with cell
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blocks, the core needle produced diagnostic material in
85% of cases (95% confidence interval (CI): 54–98),
whereas the standard needle produced diagnostic
material in 38% of the cases (95% CI: 9–76). The
core needle produced actual tissue cores 82% of the
time (95% CI: 48–98) and the standard needle produced
no tissue cores (95% CI: 0–71) (P = 0.03).[8]

Our study produced a 90% rate of visible tissue cores,
similar to or slightly better than that seen in other studies
of FNB needles.[4,7,12] It should be noted that the presence
of a visible core of tissue does not always correlate with
a true histologic core, as the visualize core may contain
tissue distortion, blood clot, or necrosis. Adequate tissue
was obtained for analysis in just under 98% of patients.

A larger multicenter study of the SharkCore needle was
published in 2016. This was a multicenter, retrospective
study of 226 patients. Median size of all lesions (mm):
26 (2– 150). Overall, a final cytologic diagnosis was
rendered in 81 % of specimens with a median of three
passes. When ROSE was used, diagnostic yield was
126/149 (85 %) with a median number of three passes;
without ROSE, diagnostic yield was 31/45 (69 %,
P = 0.03) with a median of three passes. Overall, a
diagnosis was rendered in 130/147 (88 %) specimens
with a median of two passes. The yield of this needle
was felt to be high with a low number of passes.[9]

Strengths of this study include its multicenter nature
and multiple experienced endosonographers performing
the studies. Limitations include the retrospective nature
of the study and the lack of uniform pathologic
specimen processing at different sites.

This study is the first analysis to date of a new
EUS‑FNB needle. The Acquire needle is similar in
design to the SharkCore needle but has differences as
well. The SharkCore and the Acquire needles both have
an opposing bevel design. The SharkCore needle has two
opposing bevels, whereas the Acquire needle has three
opposing bevels. By means of contrast, the ProCore
needle has a laterally placed, reverse facing bevel. Clearly,
this reflects the fact that the ideal design for an FNB
needle is still unknown, and to date, no prospective
studies comparing different FNB needle types exist.
Our study included 200 patients from seven centers
and all procedures were performed by experienced
endosonographers. As would be expected, solid
pancreatic masses and concerning lymph nodes were the
two most common targets for FNB. The mean number
of needle passes was three procedures, similar to that
seen in other studies of FNB.
One interesting facet of this study was that it reveals
that the so‑called “slow pull” technique of withdrawing
the stylet during needle actuations was the most
common method utilized, encompassing 74% of the
procedures. Limited published data to date suggest
that this technique may increase diagnostic yield and
accuracy when performing FNA and FNB.[10,11] Still, it
must be said that, at the present time, the ideal method
for operating FNB needles remains unknown.

Our study utilized the FNB needle in consecutive
patients with solid lesions of varying kinds. It is unclear
at this time if FNB is warranted in all solid lesions or
if this should be reserved for patients suspected of
having uncommon or unusual lesions wherein additional
tissue or histologic evaluation would be warranted. It is
the practice at many institutions to utilize FNB needles
for all solid lesions as was done in the context of
this study as the tissue obtained is felt to be of larger
quantity than what can be obtained through routine
FNA. The cost of FNB needles, including the Acquire
needle, is, in general, higher than for FNA needles
from the same vendors. We suspect that, as the cost of
FNB needles fall, they may become the standard needle
for EUS‑guided tissue acquisition of solid lesions,
leaving FNA needles to be predominately used for the
aspiration of cystic lesions, etc.
Overall, this study showed a high rate of tissue
adequacy and production of a tissue core with this
device with no adverse events seen in 200 patients.
Comparative studies of different FNB needles are
warranted in the future to help identify which needle
type and size is ideal in different clinical settings.
CONCLUSION
Overall, this study showed a high rate of tissue
adequacy and production of a tissue core with this
device with no adverse events seen in 200 patients.
Comparative studies of different FNB needles are
warranted in the future to help identify which needle
type and size is ideal in different clinical settings.

Financial support and sponsorship
Nil.

ENDOSCOPIC ULTRASOUND / VOLUME 8 | ISSUE 2 / MARCH-APRIL 2019

103

[Downloaded free from http://www.eusjournal.com on Wednesday, May 8, 2019, IP: 147.140.127.133]

Adler, et al.: Multicenter evaluation of a new EUS core biopsy needle

Conflicts of interest

There are no conflicts of interest.

7.

REFERENCES

8.

1.
2.

3.

4.
5.

6.

Folkers ME, Adler DG. Endoscopic ultrasound for non‑gastroenterologists:
What you need to know. Hosp Pract 2011;39:56‑69.
Adler DG, Jacobson BC, Davila RE, et al. ASGE guideline: Complications
of EUS. Gastrointest Endosc 2005;61:8‑12. Erratum in: Gastrointest Endosc
2005;61:502.
Affolter KE, Schmidt RL, Matynia AP, et al. Needle size has only a limited
effect on outcomes in EUS‑guided fine needle aspiration: A systematic
review and meta‑analysis. Dig Dis Sci 2013;58:1026‑34.
Levy MJ, Wiersema MJ. EUS‑guided Trucut biopsy. Gastrointest Endosc
2005;62:417‑26.
Ginès A, Wiersema MJ, Clain JE, et al. Prospective study of a Trucut
needle for performing EUS‑guided biopsy with EUS‑guided FNA rescue.
Gastrointest Endosc 2005;62:597‑601.
Thomas T, Kaye PV, Ragunath K, et al. Efficacy, safety, and predictive

104

9.

10.

11.

12.

factors for a positive yield of EUS‑guided Trucut biopsy: A large tertiary
referral center experience. Am J Gastroenterol 2009;104:584‑91.
Lee JH, Choi KD, Kim MY, et al. Clinical impact of EUS‑guided Trucut
biopsy results on decision making for patients with gastric subepithelial
tumors ≥2 cm in diameter. Gastrointest Endosc 2011;74:1010‑8.
Adler DG, Witt B, Chadwick B, et al. Pathologic evaluation of a new
endoscopic ultrasound needle designed to obtain core tissue samples:
A pilot study. Endosc Ultrasound 2016;5:178‑83.
DiMaio CJ, Kolb JM, Benias PC, et al. Initial experience with a novel
EUS‑guided core biopsy needle (SharkCore): Results of a large
North American multicenter study. Endosc Int Open 2016;4:E974‑9.
Chen JY, Ding QY, Lv Y, et al. Slow‑pull and different conventional
suction techniques in endoscopic ultrasound‑guided fine‑needle aspiration
of pancreatic solid lesions using 22‑gauge needles. World J Gastroenterol
2016;22:8790‑7.
Nakai Y, Isayama H, Chang KJ, et al. Slow pull versus suction in
endoscopic ultrasound‑guided fine‑needle aspiration of pancreatic solid
masses. Dig Dis Sci 2014;59:1578‑85.
Lee JH, Cho CJ, Park YS, et al. EUS‑guided 22‑gauge fine needle biopsy
for the diagnosis of gastric subepithelial tumors larger than 2 cm. Scand
J Gastroenterol 2016;51:486‑93.

ENDOSCOPIC ULTRASOUND / VOLUME 8 | ISSUE 2 / MARCH-APRIL 2019

